使用Alpha-SPECT Mini和伽马计数对乳腺、前列腺和胶质母细胞瘤模型中镥-177放射性药物的生物分布分析

Background: Radiopharmaceuticals play a pivotal role in both diagnostic imaging and targeted radionuclide therapy for cancer. With the increase in clinical use and expansion of oncology indications, accurate characterization of their biodistribution is essential to optimize tumor targeting and reduce systemic toxicity. This study utilizes two approaches, the Alpha-SPECT Mini imaging system and gamma counts, to evaluate the in vivo distribution of radiopharmaceutical agents across three clinically relevant tumor types: human mammary gland adenocarcinoma, prostate carcinoma, and glioblastoma. By utilizing these two methods we aimed to improve profiling of radioligand uptake and clearance patterns across various tumor types and radiopharmaceuticals. Methods: Subcutaneous xenografts of MDA-MB-231 human mammary gland adenocarcinoma, 22Rv1 and LNCaP human prostate carcinoma, and orthotopic xenografts of U-87 MG-Luc2 human glioblastoma in athymic nude mice were treated with lutetium-177 ( 177 Lu) conjugated Anti-human CD44 (10 µCi), 177 Lu-Anti-human PSMA (20-22 µCi or 10 µCi), or 177 Lu-Anti-human EGFRvIII (10 µCi), respectively, at a mean start size of 300 mm 3 (subcutaneous) or 3 weeks post cell implant (orthotopic). Alpha-SPECT Mini imaging was performed at 24, 72 and 168 hours post-dose and tissues for gamma counts were collected at 4, 24, 48, 72, and 168 hours post-dose. Results: Preferential uptake of the radioligand in the tumor was apparent by 24 hours post-dose in the LNCaP, 22Rv1 and U87 MG-Luc2 xenografts, while the MDA-MB-231 xenograft had lower concentrations in comparison to the liver, serum, spleen and whole blood. By 48 hours, only the liver and spleen had higher concentrations than the MDA-MB-231 tumor. Radioligand clearance was observed as early as 48 hours in the MDA-MB-231 tumors. Alpha-SPECT Mini showed similar biodistribution and dynamics of the radioligands to the gamma counts. Conclusions: Alpha-SPECT Mini imaging and gamma counting provided complementary profiling of radiopharmaceutical biodistribution across tumor types. Tumor-specific uptake patterns were evident, differences in radioligand retention, clearance, and off-target accumulation were observed. These findings underscore the importance of tumor biology in radiopharmaceutical pharmacokinetics and highlight the value of multimodal approaches for accurate profiling and therapeutic optimization.